Metal-Polyphenol Nanoparticles for Low-Toxicity Nucleic Acid Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current nanoparticle delivery systems for nucleic acid drugs, particularly those based on cationic and ionizable lipids, suffer from cytotoxicity and immunogenicity, limiting their clinical application.

Innovation Solution

A metal-chelated polyphenol complex nanoparticle system is developed, utilizing a coordination bond between a polyphenol molecular moiety and a metal ion moiety, combined with a particle aggregation-inhibiting conjugated lipid and non-cationic or non-ionizable lipids, to form a delivery system that encapsulates nucleic acids without using cationic or ionizable lipids.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cationic lipid or ionizable lipid is used as the main component of nanoparticles for adsorption of nucleic acids, then the delivery effectiveness of nucleic acids is improved, but the cytotoxicity and immunogenicity increase

Engineering Contradiction:
Improvedelivery effectivenessVSAvoidcytotoxicity and immunogenicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent removes cationic and ionizable lipids from the nanoparticle composition entirely, replacing them with a metal-chelated polyphenol complex system. This extraction of harmful components eliminates the source of cytotoxicity and immunogenicity while maintaining nucleic acid delivery capability through alternative mechanisms.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs a composite material system consisting of metal ions (Fe3+, Al3+), polyphenol molecules (curcumin, hesperetin, catechin), and neutral lipids. This composite approach creates a multifunctional nanoparticle that achieves both safe biocompatibility and effective nucleic acid delivery without relying on toxic cationic or ionizable lipids.

Inventive Principle:
Principle #40Composite materials

2Reliability

If cationic liposome is used to deliver drugs to target cells, then the delivery capability is improved, but the toxic effect on normal cells increases

Engineering Contradiction:
Improvedelivery capabilityVSAvoidtoxic effect
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts and removes cationic lipids from the delivery system, eliminating the source of toxic effects on normal cells. The replacement system uses metal-chelated polyphenol complexes with neutral lipids that provide delivery capability without the harmful toxic effects associated with cationic liposomes.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent fundamentally changes the charge parameter of the nanoparticle system from positive (cationic) to neutral. This parameter change eliminates the electrostatic interactions that cause toxicity to normal cells while maintaining the ability to deliver therapeutic agents through alternative binding mechanisms involving metal coordination and hydrophobic interactions.

Inventive Principle:
Principle #35Parameter changes

3Duration of action of stationary object

If nanoparticles are used to encapsulate nucleic acid drugs, then the protection from nuclease degradation and circulation time are improved, but the cytotoxicity and immunogenicity remain high

Engineering Contradiction:
Improvecirculation timeVSAvoidcytotoxicity and immunogenicity
Core Design Contradiction:
Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent removes cationic and ionizable lipids from the nanoparticle formulation, eliminating the source of cytotoxicity and immunogenicity. The resulting nanoparticles provide nuclease protection and extended circulation time through alternative mechanisms involving metal-chelated polyphenol complexes and neutral lipids that are biocompatible and non-immunogenic.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses a composite material system of metal ions, polyphenol molecules, and neutral lipids to create nanoparticles that simultaneously achieve nuclease protection, extended circulation time, and low cytotoxicity. The polyphenol molecules provide antioxidant and protective properties, while the metal ions enable coordination-based nucleic acid binding without requiring toxic cationic charges.

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The system reduces toxicity and improves biological safety while effectively delivering nucleic acids, facilitating their delivery and expression in cells, with reduced cytotoxicity and immunogenicity compared to existing lipid-based systems.

Implementation Method 1

the metal ion moiety and the polyphenol molecular moiety are connected by a coordination bond

Methodology Applied
Scientific EffectCoordination bond: Chemical Bonding

Implementation Method 2

The mechanism by which nanoparticles encapsulate nucleic acids is the adsorption of negatively charged nucleic acids by positively charged cationic lipid

Methodology Applied
Scientific EffectAdsorption: Adsorption

Data Source

PatentEP4606388A9Metal-polyphenol complex particle, drug-lipid particle, method for preparing same, and use thereof
Publication Date: 2026.02.25 HUNAN LONSTAR BIOTECH CO LTD
  • EP4606388A9 patent drawingFigure 1-1~1-2
  • EP4606388A9 patent drawingFigure 1-3~1-4
  • EP4606388A9 patent drawingFigure 1-5~1-7

AI summary

The disclosure relates to the technical field of biological medecines, and particularly provides a metal-chelated polyphenol complex nanoparticle, a drug-lipid particle, preparation methods for the same, and the uses thereof. The present disclosure provides a metal-chelated polyphenol complex as a carrier for drugs for stability, delivery and the like, so that it interacts with other carriers to form a metal-chelated polyphenol complex nanoparticle for effective administration of negatively charged drug. High-efficiency systemic drug delivery can be achieved, while toxicity is significantly reduced compared to LNP containing cationic or ionizable lipids, enabling safe and effective treatment of diseases or disorders.